Enoxaparin followed by once-weekly idrabiotaparinux versus enoxaparin plus warfarin for patients with acute symptomatic pulmonary embolism: a randomised, double-blind, double-dummy, non-inferiority trial
about
Idraparinux or idrabiotaparinux for long-term venous thromboembolism treatment: a systematic review and meta-analysis of randomized controlled trialsEvaluation of optical detection platforms for multiplexed detection of proteins and the need for point-of-care biosensors for clinical usePentasaccharides for the prevention of venous thromboembolism.Phase III trials of new oral anticoagulants in the acute treatment and secondary prevention of VTE: comparison and critique of study methodology and results.Measures of vitamin K antagonist control reported in atrial fibrillation and venous thromboembolism studies: a systematic reviewBenchmark for time in therapeutic range in venous thromboembolism: a systematic review and meta-analysis.Anticoagulant treatment of pulmonary embolism: impact and implications of the EINSTEIN PE study.Sample Size Estimation for Non-Inferiority Trials: Frequentist Approach versus Decision Theory Approach.Potential role of new anticoagulants for prevention and treatment of venous thromboembolism in cancer patients.Respiratory review of 2013: pulmonary thromboembolism.Management of bleeding in patients receiving conventional or new anticoagulants: a practical and case-based approach.Management of venous thromboembolism--controversies and the future.New prospective for the management of low-risk pulmonary embolism: prognostic assessment, early discharge, and single-drug therapy with new oral anticoagulants.The value of inhibitors of factor Xa for the treatment of pulmonary embolism.Index clinical manifestation of venous thromboembolism predicts early recurrence type and frequency: a meta-analysis of randomized controlled trials.How to effectively manage the event of bleeding complications when using anticoagulants.Bioequipotency of idraparinux and idrabiotaparinux after once weekly dosing in healthy volunteers and patients treated for acute deep vein thrombosis.Challenging pulmonary embolism - A new generation of oral anticoagulants.Oral anticoagulants--a frequent challenge for the emergency management of acute ischemic stroke.Comparison of idrabiotaparinux with vitamin K antagonists for prevention of thromboembolism in patients with atrial fibrillation: the Borealis-Atrial Fibrillation Study.Diagnosis and anticoagulant treatment.Validation of the Ottawa prognostic score for the prediction of recurrent venous thromboembolism in patients with cancer-associated thrombosis.Edoxaban for the long-term treatment of venous thromboembolism: rationale and design of the Hokusai-venous thromboembolism study--methodological implications for clinical trials.Pentasaccharides for the treatment of deep vein thrombosis.
P2860
Q21090694-FBFA3E0E-3820-4779-BE6D-E0A8D12C37AFQ28652076-4E44DC89-9C5B-45B6-9719-0EEC6818169CQ33436419-D44CA1B5-5FED-4DB3-BC77-913F82EF1DA0Q33663404-E3C329CD-D323-4E49-A509-B6267186009AQ33795571-900CCED7-90D7-415A-8C30-D1AA39A68CA9Q34437785-170A6203-39CC-4B8B-8AB9-432177C3CDF9Q34640824-2E42F7F8-96F4-4EAD-8B08-0AD0903263C3Q35664152-1FC4E6C8-5000-4E48-AC92-930A8C19B98DQ36839479-40320886-C7CC-4E5D-BCB4-03B81FA09F92Q37213987-E20580C7-44F4-4E9C-9318-A56EFC1A8562Q38049617-BF045B31-D256-4BDE-ADDE-151D06D32D16Q38093286-B71FEEDC-D538-4DC1-8651-A01D820C5B78Q38166368-1F966A3A-AD96-40BD-A66E-DC5B6B0E6E0BQ38215672-5A9D7582-B906-4FA1-B336-15B3BDEB2CFCQ38395008-0D00AA69-2765-44E3-A385-0D72E77EE0A3Q38634835-D1D7A76B-FD5A-4636-AA2A-A33C5E1DAFBDQ40086699-EE5C3948-5D84-4057-A25A-75FA3BD7AA8DQ41843287-3EF2BFE3-C3FC-4B2E-BE55-62709AA2E013Q44115938-EDF8ABF3-CF0A-4A2B-96AE-18F5A8C0A6E3Q44558812-BA8F65D7-B215-4222-AB58-8A5A34780F63Q45847579-0462E2A9-2C88-4551-A1C1-3F820DB8D96BQ46497825-B0C1CD00-8133-4DDB-A98D-834406A3C8C7Q46519032-39CEE120-78F8-4161-8D56-B3BD448E8FDEQ47376811-37F669E7-8C6A-4DA2-94F6-C5D86BEF159A
P2860
Enoxaparin followed by once-weekly idrabiotaparinux versus enoxaparin plus warfarin for patients with acute symptomatic pulmonary embolism: a randomised, double-blind, double-dummy, non-inferiority trial
description
2012 nî lūn-bûn
@nan
2012 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2012 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
name
Enoxaparin followed by once-we ...... e-dummy, non-inferiority trial
@ast
Enoxaparin followed by once-we ...... e-dummy, non-inferiority trial
@en
Enoxaparin followed by once-we ...... e-dummy, non-inferiority trial
@nl
type
label
Enoxaparin followed by once-we ...... e-dummy, non-inferiority trial
@ast
Enoxaparin followed by once-we ...... e-dummy, non-inferiority trial
@en
Enoxaparin followed by once-we ...... e-dummy, non-inferiority trial
@nl
prefLabel
Enoxaparin followed by once-we ...... e-dummy, non-inferiority trial
@ast
Enoxaparin followed by once-we ...... e-dummy, non-inferiority trial
@en
Enoxaparin followed by once-we ...... e-dummy, non-inferiority trial
@nl
P2093
P1433
P1476
Enoxaparin followed by once-we ...... e-dummy, non-inferiority trial
@en
P2093
Alex S Gallus
Gary E Raskob
Gerard Pillion
Harry R Büller
Martin H Prins
P356
10.1016/S0140-6736(11)61505-5
P407
P577
2012-01-14T00:00:00Z